Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 18Prostatic Neoplasms 16Breast Neoplasms 11Recurrence 8Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Colorectal Neoplasms 6Ovarian Neoplasms 5Myelodysplastic Syndromes 5Multiple Myeloma 5Melanoma 5Leukemia 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Fatigue 4Vomiting 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms, Castration-Resistant 3Pain 3Oropharyngeal Neoplasms 3Nausea 3Mesothelioma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Prolactinoma × Clear all
NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Universidade Federal do Rio de Janeiro

Phase 2/3 Completed
21 enrolled 4 charts

Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡